Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites

• Main Authors: Jie Jiao, Chengzhen Li, Guanying Yu, Lei Zhang, Xiaoyan Shi, Jingdu Yan, Houjun Zhang, Peiming Guo
• Format: Article
• Language: English
• Published: BMC 2020-07-01
• Series: World Journal of Surgical Oncology
• Subjects: Efficacy; Malignant ascites; Intraperitoneal hyperthermic chemotherapy
• Online Access: http://link.springer.com/article/10.1186/s12957-020-01956-y

Abstract Objective The purpose of this study is to compare the difference of clinical efficacy between conventional intraperitoneal chemotherapy and HIPEC, so as to explore the clinical application value and advantages of HIPEC. Design A retrospective analysis was conducted on 80 patients with malignant ascites admitted to our hospital from June 2017 to June 2019. The general clinical data and qualitative data of the treatment results of 80 patients with malignant ascites were processed by SPSS19.0 using χ 2 test, and quantitative data were processed by t test. P < 0.05, statistical data can be considered statistically significant. Results 1. There was no significant change in vital signs and temperature in the observation group during the treatment, and the difference was not statistically significant. 2. The short-term total effective rate of patients in the observation group was 91.11%, and the short-term total effective rate of the patients in the control group was 40%. 3. There was no significant difference in the incidence of adverse reactions between the two groups of patients. Conclusion Intraperitoneal hyperthermic chemotherapy combined with intravenous chemotherapy can significantly control malignant ascites and has small adverse reactions, which is worthy of clinical promotion and application.